medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2008, Number 5

<< Back Next >>

Rev Mex Oftalmol 2008; 82 (5)

Experiencia con Bevacizumab (Avastin) como adyuvante previo a cirugía de vitrectomía en retinopatía diabética proliferativa avanzada

Hernández DMSE

Language: Spanish
References: 31
Page: 296-301
PDF size: 52.40 Kb.


ABSTRACT

Purpose: To evaluate de safety and efficacy of intravitreal injection of bevacizumab before vitrectomy surgery in advanced proliferative diabetic retinopathy.
Patients and methods: A randomized clinical study was performed which included 40 eyes of 40 patients. Inclusion criteria were: advanced proliferative diabetic retinopathy with tractional retinal detachment, Hb1aC‹7. Patients were randomized in two groups: in group A conventional pars plana vitrectomy (PPV) was performed and in group B PPV plus a 1.25 mg of bevacizumab intravitreal injection was 48 hours prior to surgery was performed. Basal best corrected visual acuity, intraocular pressure, clinical pictures were taken at 1 week, 1, 3 and six months postoperatively. Effective vitrectomy time was 8.05 minutes in group A versus 16.8 minutes in group B.
Results: Statistical significant differences were observed in visual capacity at 3 and 6 months follow-up between the two groups (p=0.002 and p=0.001 respectively). Mean visual acuity in group A was -0.82 logMAR and -2.01 logMAR in group B.
Conclusions: Adjuvant intravitreal injection of bevacizumab prior to vitrectomy surgery in diabetic retinopathy with tractional retinal detachment significantly eases the procedure thus diminishing intra and postoperative complications.


REFERENCES

  1. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Williston Park) 2001; 15(8):1017, 1020, 1023-6.

  2. Gragoudas ES, Adamis AP, Cunningham ET Jr y cols. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351(27):2805-16.

  3. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results.Ophthalmol Clin North Am 2006; 19(3):361-72.

  4. Michels S, Rosenfeld PJ, Puliafito CA y cols. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled openlabel clinical study. Ophthalmology 2005; 112(6):1035-47.

  5. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36(4):336-9.

  6. Avery RL, Pieramici DJ, Rabena MD y cols. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113(3):363-372.

  7. Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol 1994; 87(3):223-32.

  8. Arevalo JF, Wu L, Sanchez JG y cols. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2007; [en prensa].

  9. Ishikawa K, Honda S, Tsukahara Y y cols. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye; [en prensa].

  10. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26(6):699-700.

  11. Elliott A, Flanagan D. Macular detachment following laser treatment for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228(5):438-41.

  12. Charles S. Diabetic retinopathy vitrectomy study. Arch Ophthalmol 1986; 104(4): 486, 488.

  13. Diabetic Retinopathy Vitrectomy Study. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. (DRVS) report #1. Ophthalmology 1985; 92(4):492-502.

  14. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 1985; 103(11):1644-52.

  15. Shea M. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial-Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988; 95(10):1307-20.

  16. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial—Diabetic Retinopathy Vitrectomy Study Report 4. Ophthalmology 1988; 95(10):1321-34.

  17. Diabetic Retinopathy Vitrectomy Study Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Fouryear results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990; 108(7):958-64. Erratum in: Arch Ophthalmol 1990 Oct; 108(10):1452.

  18. Faulborn J, Conway BP, Machemer R. Surgical complications of pars plana vitreous surgery. Ophthalmology 1978; 85(2):116-25.

  19. Carter JB, Michels RG, Glaser BM y cols. Iatrogenic retinal breaks complicating pars plana vitrectomy. Ophthalmology 1990; 97(7):848-53.

  20. Chagnon A, Payan J, Levy C, Chassain C. Intraocular pressure during vitrectomy in the diabetic patient. Bull Soc Ophtalmol Fr 1989; 89(1):171-8.

  21. Thompson JT, Glaser BM, Michels RG y cols. The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 1986; 93(3):279-82.

  22. O’Grady GE. The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 1986; 93(10):1367.

  23. Imamura Y, Kamei M, Minami M y cols. Heparin-assisted removal of clotting preretinal hemorrhage during vitrectomy for proliferative diabetic retinopathy. Retina 2005; 25(6):793-5.

  24. Siam AL. External diathermy treatment of proliferative diabetic retinopathy with vitreous haemorrhage. Br J Ophthalmol 1986; 70(2):118-21.

  25. Ruiz-Moreno JM, Montero JA, Lugo F y cols. Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmol Scand 2007; [En prensa] .

  26. Yanyali A, Aytug B, Horozoglu F y cols. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007; 144(1):124-6.

  27. Haritoglou C, Kook D, Neubauer A y cols. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9):999-1005.

  28. Jonas JB, Spandau UH, Rensch F y cols. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 23(3):240-2.

  29. Arevalo JF, Maia M, Flynn H Jr y cols. Tractional Retinal Detachment following Intravitreal Bevacizumab (Avastin(R)) in patients with Severe Proliferative Diabetic Retinopathy. Br J Ophthalmol 2007; [en prensa].

  30. Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol 2007; 21(3):185-7.

  31. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007; 21(4):245-57.




2020     |     www.medigraphic.com